PIPELINE

Voyageur Pharmaceuticals is developing a pipeline of generic and new contrast media products for the radiology market

We currently have 5 products approved by Health Canada

Candidate Imaging Modality Anatomy Proof of Concept Formula Development Approvals* Test Market Commercial Launch
SmoothX 2.0% CT
  • Abdomen
  • Stomach
  • Bowel, Rectum, Colon
CND: 2021

US: 2022

EU: 2023

CND: 2021/2022

US: 2022

EU: 2023

CND: 2022

US: 2023

EU: 2023

MultiX Thick Fluoroscopy
  • Clon
CND: 2021

US: 2022

EU: 2023

CND: 2021/2022

US: 2022

EU: 2023

CND: 2022

US: 2023

EU: 2023

MultiX Thin Fluoroscopy
  • Colon
CND: 2021

US: 2022

EU: 2023

CND: 2021/2022

US: 2022

EU: 2023

CND: 2022

US: 2023

EU: 2023

HDX Fluoroscopy
  • Stomach
CND: 2021

US: 2022

EU: 2023

CND: 2021/2022

US: 2022

EU: 2023

CND: 2022

US: 2023

EU: 2023

LDX Fluoroscopy
  • Stomach
  • Small bowel
CND: 2021

US: 2022

EU: 2023

CND: 2021/2022

US: 2022

EU: 2023

CND: 2022

US: 2023

EU: 2023

VY-101 MRI
  • MR Enterography

Neutral

1H/2022

1H/2023

2H/2023

1H/2024

VY-102 (a,b,c,d) Fluoroscopy
  • Esophagus

Dysphagia

1H/2022

1H/2023

2H/2023

1H/2024

IoXp (Iopamidol) Fluoro / CT
  • Blood vessels, organs, tissues

2H/2022

1H/2024

2H/2024

1H/2025

IoXh (Iohexol) Fluoro / CT
  • Blood vessels, organs, tissues

2H/2022

1H/2024

2H/2024

1H/2025

VY-103 Fluoro / CT
  • Spine

ESI

2H/2022

1H/2024

2H/2024

1H/2025

  • Candidate
  • Imaging Modality
  • Anatomy
  • Proof of Concept
  • Formula Development
  • Approvals*

Neuropathic Pain

4ET1103

IND-Enabling

Migraine Pain

MNK-elF4E

Discovery

Acute Pain

GPCR ENRICHED IN HUMAN DRG NEURONS

Discovery

Publications